Morgan Stanley raised the firm’s price target on Fresenius Medical (FMS) to EUR 39 from EUR 37 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Divests Laboratory Assets to Quest Diagnostics
- Fresenius Medical divesting select laboratory assets to Quest Diagnostics
- Is FMS a Buy, Before Earnings?
- Fresenius Medical price target raised to EUR 46.50 from EUR 41 at Citi
- Fresenius Medical price target raised to EUR 55 from EUR 47 at Berenberg